AxoGen (NASDAQ:AXGN) Upgraded to Buy by StockNews.com

StockNews.com upgraded shares of AxoGen (NASDAQ:AXGN) from a hold rating to a buy rating in a report released on Wednesday.

A number of other equities research analysts also recently weighed in on AXGN. Canaccord Genuity Group reaffirmed a buy rating and set a $15.00 price objective on shares of AxoGen in a research report on Thursday, June 20th. Raymond James began coverage on AxoGen in a report on Monday, July 1st. They issued an outperform rating and a $13.00 price target on the stock. Finally, JMP Securities boosted their price objective on AxoGen from $17.00 to $20.00 and gave the company a market outperform rating in a research report on Friday, August 9th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of Buy and a consensus price target of $13.80.

AxoGen Trading Down 0.1 %

NASDAQ:AXGN opened at $13.79 on Wednesday. AxoGen has a 52 week low of $3.45 and a 52 week high of $15.08. The company has a quick ratio of 2.32, a current ratio of 3.51 and a debt-to-equity ratio of 0.70. The company has a market cap of $602.69 million, a PE ratio of -27.58 and a beta of 1.12. The business’s 50 day moving average is $11.83 and its two-hundred day moving average is $8.80.

AxoGen (NASDAQ:AXGN) last released its quarterly earnings data on Thursday, August 8th. The medical equipment provider reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.10. The firm had revenue of $47.91 million during the quarter, compared to the consensus estimate of $43.27 million. AxoGen had a negative net margin of 9.53% and a negative return on equity of 17.30%. On average, analysts predict that AxoGen will post -0.33 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Koss Olinger Consulting LLC acquired a new position in shares of AxoGen during the second quarter valued at $75,000. Lazard Asset Management LLC increased its stake in AxoGen by 30.1% during the 1st quarter. Lazard Asset Management LLC now owns 11,539 shares of the medical equipment provider’s stock valued at $93,000 after buying an additional 2,671 shares during the period. Acadian Asset Management LLC bought a new stake in shares of AxoGen during the 2nd quarter worth about $125,000. BNP Paribas Financial Markets lifted its stake in shares of AxoGen by 8.6% in the 1st quarter. BNP Paribas Financial Markets now owns 20,820 shares of the medical equipment provider’s stock worth $168,000 after acquiring an additional 1,651 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of AxoGen by 8.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 29,650 shares of the medical equipment provider’s stock valued at $240,000 after acquiring an additional 2,204 shares in the last quarter. Institutional investors and hedge funds own 80.29% of the company’s stock.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.